Previous 10 | Next 10 |
Nyxoah to Participate in the 17 th Annual Wells Fargo Securities Healthcare Conference Mont-Saint-Guibert, Belgium – August 18, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Companyȁ...
Image source: The Motley Fool. Nyxoah S.A. (NASDAQ: NYXH) Q2 2022 Earnings Call Aug 08, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Nyxoah S.A. (NYXH) Q2 2022 Earnings Call Transcript
Nyxoah press release ( NASDAQ: NYXH ): Q2 GAAP EPS of -€0.19. Revenue of €0.94M (+452.9% Y/Y) misses by €0.18M . For further details see: Nyxoah GAAP EPS of -€0.19, revenue of €0.94M misses by €0.18M
REGULATED INFORMATION Nyxoah Reports Second Quarter and First Half 2022 Financial and Operating Results DREAM enrollment complete, 12-month clinical data expected in fall of 2023 Mont-Saint-Guibert, Belgium – August 8, 2022, 10:05pm CET / 4:05pm ET...
Belgium-based- Nyxoah ( NASDAQ: NYXH ) said it signed a distribution agreement in Germany for AcuPebble SA100, a home sleep test for patients with Obstructive Sleep Apnea (OSA) developed by medical device company Acurable . Nyxoah added that AcuPebb...
Nyxoah and Acurable Enter into Distribution Agreement in Germany for the AcuPebble SA100 Home Sleep Test Mont-Saint-Guibert, Belgium – August 2, 2022, 8:00am CET / 2:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “C...
Nyxoah to Present at the Canaccord Genuity 42 nd Annual Growth Conference Mont-Saint-Guibert, Belgium – July 27, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical ...
Nyxoah to Release Second Quarter and First Half 2022 Financial Results on August 8, 2022 Mont-Saint-Guibert, Belgium – July 19, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”),...
Gainers: Apellis Pharmaceuticals APLS +22% . Neuronetics STIM +17% . Nyxoah ( NYXH ) +17% . Celyad Oncology ( CYAD ) +8% . NuCana ( NCNA ) +7% . Losers: High Tide HITI -21% . Ultragenyx Pharmaceutical ( RARE ...
Nyxoah Announces CE Mark Approval for Genio® 2.1 The next generation external activation chip leverages Nyxoah’s scalable platform to continuously enhance patient comfort and therapy efficacy Mont-Saint-Guibert, Belgium – July 18, 2022, 10:30pm CET...
News, Short Squeeze, Breakout and More Instantly...
Nyxoah Appoints Scott Holstine as Chief Commercial Officer Mont-Saint-Guibert, Belgium – July 15, 2024, 8:00am CET / 2:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the ...
REGULATED INFORMATION INSIDE INFORMATION Nyxoah Has Signed a €37.5 Million Loan Facility Agreement with the European Investment Bank Mont-Saint-Guibert, Belgium – July 3, 2024, 12:30pm CET / 6:30am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (&...
Nyxoah Submits Fourth and Final Module in PMA Application for Genio to the US FDA Mont-Saint-Guibert (Belgium), July 1, 2024 , 8:00am CET / 2:00am ET – (“Nyxoah” or the “Company”), a medical technology company focused on the develop...